Pfizer and Moderna stocks rise on FDA approval of booster shots
Pfizer and Moderna stocks move higher on Friday after the FDA authorized mRNA booster shots for all adults. Yahoo Finance's Akiko Fujita reports.
Video Transcript
AKIKO FUJITA: Let's turn our attention to two stocks that are moving to the upside in the session. And that is Pfizer and Moderna. Pfizer actually hitting a new high, up about half a percentage point here, after the FDA authorized COVID-19 booster shots for all adults, giving the green light to those third jabs from Pfizer and Moderna. Now, those who got their vaccinations will be eligible for a booster six months after their second shot if you got Pfizer or Moderna. Those who got the Johnson & Johnson vaccine will be eligible for a booster just two months after their first shot.
A CDC committee is meeting this afternoon. If that panel approves the booster shots, it could be available as early as this weekend. Moderna getting a big pop there, up about almost 5%. And of course, we should mention the approvals here coming as fears of another wave this winter, a COVID wave, are increasingly growing bigger. So we'll be watching that one closely.
